Preparation, Pharmacokinetics and Body Distribution of Silymarin-Loaded Solid Lipid Nanoparticles After Oral Administration
The purpose of this study was to investigate the body distribution of silymarin incorporated into solid lipid nanoparticles (SLNs) after oral administration. Silymarin-loaded solid lipid nanoparticles (SM-SLNs) were developed using Compritol 888 ATO, soybean lecithin and poloxamer 188.
Two kinds of SM-SLNs were prepared using a hot and cold homogenization method. The particle size distribution, zeta potential, drug-loading (DL), and entrapment efficiency (EE) were investigated in detail. The in vitro release of both SM-SLNs preparations was studied by a bulk-equilibrium
reverse dialysis bag technique at pH 7.4 using phosphate-buffered saline. The concentrations of silybin were determined by high-performance liquid chromatography. The in vitro release experiments showed that a prolonged drug release can be achieved from the SM-SLNs produced by cold
homogenization (cold-SM-SLNs). Therefore, cold-SM-SLNs were used for all further body distribution studies. The relative bioavailability of the cold-SM-SLNs was 2.79-fold higher compared to the SM suspension. Except for the kidneys, the AUC of the cold-SM-SLNs was higher in all tested organs
than that of the SM suspension including the liver. The results indicated that the cold-SM-SLNs can improve the oral bioavailability of SM and this might be used for the oral drug targeting system for SM to the liver.
Keywords: BODY DISTRIBUTION; PHARMACOKINETICS; SILYMARIN; SOLID LIPID NANOPARTICLES
Document Type: Research Article
Publication date: 01 June 2007
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content